<DOC>
	<DOCNO>NCT02172872</DOCNO>
	<brief_summary>Older patient acute myeloid leukemia ( AML ) small ( &lt; 10 % ) chance long-term survival . Despite treatment elderly AML patient intensive chemotherapy , survival improve last decade . The purpose study determine whether frontline therapy 10-day decitabine schedule provide well survival standard intensive combination chemotherapy elderly AML patient ( &gt; = 60 year ) .</brief_summary>
	<brief_title>`` InDACtion '' v `` 3+7 '' Induction AML</brief_title>
	<detailed_description>- The overall survival ( OS ) old AML patient improve last decade intensive chemotherapy base cytarabine combine anthracycline ( `` 3+7 '' ) . - Next generation sequence technology reveals mutation gene involve epigenetics frequently mutate AML ( e.g . DNMT3a ) , suggest important role epigenetics pathophysiology AML . Decitabine ( give 5-day schedule ) show superior low-dose Ara-C. - A retrospective analysis reveal epigenetic therapy ( either azacitidine decitabine ) associate similar survival rate intensive chemotherapy old patient ( n=671 ) newly diagnose AML . - The recently publish encouraging phase 2 data 10-day decitabine schedule suggest decitabine result similar CR rate compare intensive chemotherapy . Allogeneic transplantation ( alloHCT ) also offer opportunity cure among old AML patient , therefore treatment strategy aim allograft old AML patient . - Decitabine treatment lead interesting cure rate use `` bridging '' allografting . Based data summarize , hypothesize decitabine daily dose 20 mg/m² start 10-day schedule follow alloHCT continuation 5-days decitabine cycle superior conventional intensive chemotherapy old AML patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion criterion : 1 . Age ≥ 60 year 2. WHO Performance status ≤ 2 3 . Eligible standard intensive chemotherapy 4 . Newly diagnose AML cytopathologically confirm WHO classification ( 2 month prior randomization ) 5 . De novo secondary AML allow 6 . White blood cell ( WBC ) count ≤ 30x10E9/L ( measure within 72 hour prior randomization ) . 7 . Laboratory assessment ( measure within 7 day prior randomization ) : 1. serum glutamate oxaloacetate transaminase ( SGOT / ASAT ) serum glutamate pyruvate transaminase ( SGPT / ALAT ) &lt; 2.5 x upper limit normal range unless consider AMLrelated 2 . Total serum bilirubin &lt; 2.5 x upper limit normal range unless consider AMLrelated due Gilbert 's syndrome 3 . Serum creatinine &lt; 2.5 x upper limit normal range unless consider AMLrelated 8 . Patients reproductive potential use adequate birth control measure , define investigator , study treatment period least 3 month last study treatment . 9 . Before patient registration/randomization , write informed consent must give accord International Conference Harmonization good clinical practice ( ICH GCP ) national/local regulation Exclusion criterion : 1 . Presence acute promyelocytic leukemia ( APL , i.e . AMLM3 ( 15 ; 17 ) ( q22 ; q12 ) ; promyelocytic leukemia retinoic acid receptoralpha ( PMLRARA ) fusion gene cytogenetic variant ) 2 . Presence blast crisis chronic myeloid leukemia 3 . Presence active central nervous system ( CNS ) leukemia 4 . Patients receive prior treatment AML ( relapse AML allow ) , antileukemic therapy include investigational agent hypomethylating agent ( decitabine , 5azacytidine ) . Treatment hydroxyurea ( HU ) allow control leukocytosis give maximum 5 day stop least two day prior start protocol regimens 5 . Patients receive prior treatment myelodysplastic syndrome ( MDS ) myeloproliferative neoplasm ( MPN ) : 1. hypomethylating agent ( decitabine , 5azacytidine ) , OR 2. intensive chemotherapy transplantation within last three year 3 . NOTE : The follow treatment previous MDS MPN allow ( one month inclusion ) : Growth factor , thrombomimetics , immunosuppression ( cyclosporin A , steroid , antithymocyte globulin etc . ) , chelation , interferon , anagrelide Lenalidomide , lowdose chemotherapy ( lowdose melphalan , HU , lowdose cytarabine etc . ) , tyrosinekinase inhibitor , histone deacetylase inhibitor ( e.g . valproic acid , panobinostat etc . ) , mammalian target rapamycin ( mTOR ) inhibitor , experimental treatment base inhibition deoxyribonucleic acid ( DNA ) methyltransferase 6 . Presence concomitant severe cardiovascular disease would make intensive chemotherapy impossible 7 . Presence concomitant malignancy require chemotherapy malignancy ( except basal squamous cell carcinoma skin ) patient receive chemotherapy within 6 month prior randomization NOTE : Diagnosis previous concomitant malignancy thus exclusion criterion . 8 . Presence active uncontrolled infection 9 . Presence psychological , familial , sociological geographical condition opinion investigator potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Newly diagnose</keyword>
	<keyword>AML</keyword>
	<keyword>Elderly</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Transplant</keyword>
</DOC>